By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aclaris Therapeutics 

101 Lindenwood Drive
Suite 400
Malvern  Pennsylvania  19355  U.S.A.
Phone: 484-324-7933 Fax: 484-324-7949



Company News
Aclaris (ACRS) Reports Third Quarter 2015 Financial Results 11/19/2015 8:12:02 AM
Aclaris (ACRS) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares 10/14/2015 10:31:44 AM
Aclaris (ACRS) Closes $56.5M IPO 10/14/2015 8:45:52 AM
Aclaris (ACRS) Announces Pricing Of IPO 10/7/2015 7:24:16 AM
Aclaris Therapeutics Sets Terms for $75 Million IPO 9/28/2015 6:59:34 AM
Aclaris Therapeutics Nabs $40 Million, Strikes Skin Disorders Pact with Rigel (RIGL) 9/9/2015 11:02:21 AM
Rigel (RIGL) And Aclaris Therapeutics Sign License Agreement For JAK Inhibitors To Treat Skin Disorders 9/9/2015 7:01:40 AM
Aclaris Therapeutics' Lead Drug Candidate A-101 Achieves Statistically Significant Results In Third Phase 2 Clinical Trial For Seborrheic Keratosis, A Common Type Of Benign Skin Tumor 3/17/2015 9:47:56 AM
Aclaris Therapeutics Announces Positive Results From Phase 2b Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Benign Skin Tumor 1/27/2015 6:38:13 AM
Aclaris Therapeutics Locks In $21 Million Series B Financing 10/2/2014 10:47:06 AM